Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


UK Attacks Pandemic With Funding For Drug And Vaccine Trials

Biotech Industry Body Assembles COVID-19 Task Force

Executive Summary

Efforts are under way in the UK on many fronts to develop new treatments and vaccines for coronavirus infection, including researching new uses of existing products and clinical trials of new vaccines.

You may also be interested in...

Coronavirus Update: After Green Light In Canada, US Awaits Pfizer/BioNTech Vaccine Authorization

Pfizer and BioNTech's COVID-19 vaccine picks up its third emergency authorization, with all eyes now on the final decision from the US FDA. Elsewhere, there are changes at the UK's vaccine taskforce, while Korea is moving ahead with vaccine development plans.  

COVID-19: UK Sets Up Key Vaccine Taskforce; Funds 21 New Research Projects

The UK government believes its new Vaccine Taskforce will be essential in coordinating efforts to rapidly accelerate the development and manufacture of a potential new coronavirus vaccine.

UK MHRA: COVID-19 To Spark Rise In Clinical Trial-Related Deviations

The UK’s Medicines and Healthcare products Regulatory Agency says that any increase in clinical trial protocol deviations in relation to coronavirus outbreak will not constitute a serious breach.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts